Abstract:BACKGROUND:Stem cell transplantation offers a promising treatment for heart failure. Recent studies show that both c-kit positive cardiac stem cells (CSCs) and bone marrow-derived mesenchymal stem cells (BM-MSCs) are good candidates for stem cell therapy to treat heart failure; however, the exact mechanism of stem cell therapy in improving cardiac function of ischemic cardiomyopathy is not fully known. Our objective was to test our hypothesis that CSCs and/or BM-MSCs repair the damaged heart by boosting post-myocardial infarction (MI) angiogenesis in a paracrine manner. METHODS AND RESULTS:We isolated and purified CSCs and BM-MSCs from rats. Intramyocardial injections of CSCs and/or BM-MSCs were performed at 28 days after MI. We applied cardiac ultrasound and histological analysis to evaluate the effect of cell therapy on cardiac function and cardiac remodeling. In vivo donor cell transplantation experiments showed that CSCs and/or BM-MSCs improved cardiac function after MI and reduced infarct size. However, in vivo cell tracking experiments showed that minimal donor cells remained in the myocardium after cell transplantation. Our further in vitro and in vivo experiments showed that transplantation of CSCs enhanced the expression of pro-angiogenic factors and boosted post-MI angiogenesis in the myocardium in a paracrine manner, which in part contributed to the effect of CSCs on cardiac recovery after MI. CSCs and BM-MSCs synergistically inhibited CSC/BM-MSC apoptosis and enhanced their proliferation in a paracrine manner. This resulted in a larger number of transplanted cells remaining in the post-MI myocardium after coinjection of CSCs and BM-MSCs, and therefore the accumulation of more pro-angiogenic factors in the heart tissue compared to transplantation of CSCs or MSCs alone. Consequently, transplantation of both CSCs and BM-MSCs was superior to transplantation of either CSCs or BM-MSCs alone to boost post-MI angiogenesis and improve cardiac function after MI. CONCLUSION:C-kit+ CSC and/or BM-MSC transplantation can improve cardiac function after MI in a paracrine manner. Coinjection of both CSCs and BM-MSCs improves cardiac function more significantly than CSC or BM-MSC transplantation alone in a paracrine manner by improving the engraftment of donor cells and boosting the expression of multiple pro-angiogenic factors.

Angiopoietin-1 Preconditioning Enhances Survival and Functional Recovery of Mesenchymal Stem Cell Transplantation

Transplantation of Hypoxia-Preconditioned Mesenchymal Stem Cells Improves Infarcted Heart Function Via Enhanced Survival of Implanted Cells and Angiogenesis

Anoxic preconditioning: A way to enhance the cardioprotection of mesenchymal stem cells

The Antiapoptotic Effect of Mesenchymal Stem Cell Transplantation on Ischemic Myocardium is Enhanced by Anoxic Preconditioning.

Angiopoietin-1 Protects Mesenchymal Stem Cells Against Serum Deprivation and Hypoxia-Induced Apoptosis Through the PI3K/Akt Pathway

C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner.

Improved Anti-Apoptotic and Anti-Remodeling Potency of Bone Marrow Mesenchymal Stem Cells by Anoxic Pre-Conditioning in Diabetic Cardiomyopathy.

Preconditioning is an Effective Strategy for Improving the Efficiency of Mesenchymal Stem Cells in Kidney Transplantation

Long-Term Outcome Of Administration Of Hypoxia-Preconditioned Mesenchymal Stem Cells After Acute Myocardial Infarction In Nonhuman Primate Angiogenesis Persist For At Least 17 Months

The Protective Effect of Bone Marrow Mesenchymal Stem Cells by Anoxic Preconditioning on Diabetic Cardiomyopathy

Preconditioning of bone marrow mesenchymal stem cells by prolyl hydroxylase inhibition enhances cell survival and angiogenesis in vitro and after transplantation into the ischemic heart of rats

Preconditioning Enhances Cell Survival and Differentiation of Stem Cells During Transplantation in Infarcted Myocardium.

Therapeutic Potential of Angiogenin Modified Mesenchymal Stem Cells: Angiogenin Improves Mesenchymal Stem Cells Survival under Hypoxia and Enhances Vasculogenesis in Myocardial Infarction.

Transplantation of Hypoxia Preconditioned Bone Marrow Mesenchymal Stem Cells Enhances Angiogenesis and Neurogenesis after Cerebral Ischemia in Rats.

Pretreatment of Mesenchymal Stem Cells with Angiotensin II Enhances Paracrine Effects, Angiogenesis, Gap Junction Formation and Therapeutic Efficacy for Myocardial Infarction

Bone Marrow Mesenchymal Stem Cells Induce Angiogenesis and Attenuate the Remodeling of Diabetic Cardiomyopathy

Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction

Effects of Mesenchymal Stem Cells Transplantation on Post-Infarction Ventricular Remodeling in Rats

Mesenchymal Stem Cells Preconditioned with Trimetazidine Promote Neovascularization of Hearts under Hypoxia/Reoxygenation Injury

Overexpression of MicroRNA-1 Improves the Efficacy of Mesenchymal Stem Cell Transplantation after Myocardial Infarction.

Experimental research on treatment of myocardial infarction by stem cells pretreated with endothelial cell-specific molecule-1